BEGIN:VCALENDAR VERSION:2.0 PRODID:IEEE vTools.Events//EN CALSCALE:GREGORIAN BEGIN:VTIMEZONE TZID:Europe/London BEGIN:DAYLIGHT DTSTART:20250330T020000 TZOFFSETFROM:+0000 TZOFFSETTO:+0100 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3 TZNAME:BST END:DAYLIGHT BEGIN:STANDARD DTSTART:20241027T010000 TZOFFSETFROM:+0100 TZOFFSETTO:+0000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10 TZNAME:GMT END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTAMP:20241104T145833Z UID:F669E0C0-2DF8-4B54-AABE-1CB4EE84AEA3 DTSTART;TZID=Europe/London:20241030T143000 DTEND;TZID=Europe/London:20241030T160000 DESCRIPTION:Point-of-care (POC) diagnostic devices hold great promise to si gnificantly impact healthcare delivery and address health disparities. The se devices enable a shift in focus away from the utilization of high-cost specialized care for the treatment of late-stage diseases toward predictiv e\, preventative\, participatory\, and personalized healthcare for more ef fective disease monitoring and management.\n\nIn this seminar\, I will pre sent our work on ClotChip® – a microfluidic sensor that utilizes dielec tric spectroscopy for POC assessment of blood coagulation disorders with < 10 µL of whole blood. Specifically\, I will analyze a simple circuit mode l that accurately captures the frequency-dependent dielectric behavior of human whole blood placed within a microfluidic channel. I will then discus s how temporal variation in the dielectric properties of a coagulating blo od sample at 1 MHz provides information about cellular (i.e.\, platelet) a nd non-cellular (i.e.\, coagulation factor) abnormalities in clot formatio n\, as well as about the fibrinolytic system that regulates clot resolutio n to prevent thrombotic occlusions.\n\nFinally\, to establish the utility of ClotChip® as a platform technology for POC assessment of hemostasis\, I will share our results from pilot clinical studies with ClotChip® on mo nitoring anticoagulation therapy with direct oral anticoagulants (DOACs) – a new class of FDA-approved blood thinners – as well as coagulation factor replacement therapy in hemophilia care management. Results from cor relative studies between ClotChip® and clinically relevant global hemosta tic assays such as rotational thromboelastometry (ROTEM) are also provided .\n\nSpeaker(s): Pedram\, \n\nRoom: 807\, Bldg: Roberts Building\, Barlow Room (Room 807)\, \, Malet Place\, \, London \, England\, United Kingdom\, WC1E 7JE\, Virtual: https://events.vtools.ieee.org/m/438429 LOCATION:Room: 807\, Bldg: Roberts Building\, Barlow Room (Room 807)\, \, M alet Place\, \, London \, England\, United Kingdom\, WC1E 7JE\, Virtual: h ttps://events.vtools.ieee.org/m/438429 ORGANIZER:a.demosthenous@ucl.ac.uk SEQUENCE:17 SUMMARY:Microfluidic Dielectric Biosensors for Point-of-Care Assessment of Hemostasis: From Conceptualization to Clinical Translation URL;VALUE=URI:https://events.vtools.ieee.org/m/438429 X-ALT-DESC:Description: <br /><p class="MsoNormal" style="margin-bottom: 5. 0pt\; text-align: justify\; text-indent: 18.0pt\;"><span style="font-famil y: 'Arial'\,sans-serif\; mso-bidi-font-weight: bold\;">Point-of-care (POC) diagnostic devices hold great promise to significantly impact healthcare delivery and address health disparities. These devices enable a shift in f ocus away from the utilization of high-cost specialized care for the treat ment of late-stage diseases toward predictive\, preventative\, participato ry\, and personalized healthcare for more effective disease monitoring and management.</span></p>\n<p class="MsoNormal" style="margin-bottom: 5.0pt\ ; text-align: justify\; text-indent: 18.0pt\;"><span style="font-family: ' Arial'\,sans-serif\; mso-bidi-font-weight: bold\;">In this seminar\, I wil l present our work on ClotChip<sup>&reg\;</sup> &ndash\; a microfluidic se nsor that utilizes dielectric spectroscopy for POC assessment of blood coa gulation disorders with &lt\;10 &micro\;L of whole blood. Specifically\, I will analyze a simple circuit model that accurately captures the frequenc y-dependent dielectric behavior of human whole blood placed within a micro fluidic channel. I will then discuss how temporal variation in the dielect ric properties of a coagulating blood sample at 1 MHz provides information about cellular (i.e.\, platelet) and non-cellular (i.e.\, coagulation fac tor) abnormalities in clot formation\, as well as about the fibrinolytic s ystem that regulates clot resolution to prevent thrombotic occlusions.</sp an></p>\n<p class="MsoNormal" style="margin-bottom: 5.0pt\; text-align: ju stify\; text-indent: 18.0pt\;"><span style="font-family: 'Arial'\,sans-ser if\; mso-bidi-font-weight: bold\;">Finally\, to establish the utility of C lotChip<sup>&reg\;</sup> as a platform technology for POC assessment of he mostasis\, I will share our results from pilot clinical studies with ClotC hip<sup>&reg\;</sup> on monitoring anticoagulation therapy with direct ora l anticoagulants (DOACs) &ndash\; a new class of FDA-approved blood thinne rs &ndash\; as well as coagulation factor replacement therapy in hemophili a care management. Results from correlative studies between ClotChip<sup>& reg\;</sup> and clinically relevant global hemostatic assays such as rotat ional thromboelastometry (ROTEM) are also provided.</span></p> END:VEVENT END:VCALENDAR